

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Rockefeller University Fisher Drug Discovery Core Facility

RRID:SCR_020985

Type: Tool

Proper Citation

Rockefeller University Fisher Drug Discovery Core Facility (RRID:SCR_020985)

Resource Information

URL: <http://www.rockefeller.edu/ddrc/>

Proper Citation: Rockefeller University Fisher Drug Discovery Core Facility (RRID:SCR_020985)

Description: Core guides researchers in drug discovery by improving efficiency of their bioassays, identifying compounds and targets of function, and in utilizing technologies for measurement of drug/receptor interactions. Center also has spectroscopic and calorimetric equipment for use in studies of interactions of drugs with their targets.

Abbreviations: DDRC

Synonyms: Fisher Drug Discovery Resource Center, Fisher Drug Discovery Resource Center Core Facility, Rockefeller University Fisher Drug Discovery Resource Center Core Facility

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF, HTSRC, DDRC, drug discovery, bioassays, identifying compounds and targets, drug receptor interaction measurement technology

Resource Name: Rockefeller University Fisher Drug Discovery Core Facility

Resource ID: SCR_020985

Alternate IDs: SCR_020988, ABRF_431

Alternate URLs: <https://coremarketplace.org/?FacilityID=431>

Old URLs: <http://www.rockefeller.edu/htsrc/index>

Record Creation Time: 20220129T080353+0000

Ratings and Alerts

No rating or validation information has been found for Rockefeller University Fisher Drug Discovery Core Facility.

No alerts have been found for Rockefeller University Fisher Drug Discovery Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Upmanyu K, et al. (2026) First-in-Class Small Molecule ROBO2 Binders Identified through Integrated Virtual Screening and Biophysical Validation. bioRxiv : the preprint server for biology.

Upadhyay S, et al. (2026) Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potential. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 194, 118937.

Pfau DJ, et al. (2025) High throughput screening assay for the identification of ATF4 and TFEB activating compounds. Autophagy reports, 4(1).

Calvo-Barreiro L, et al. (2025) Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small Molecules. ACS omega, 10(44), 53612.

Abdo AN, et al. (2025) Identification of a First-In-Class Small Molecule CAPON Binder Using Affinity Selection-Mass Spectrometry Screening. bioRxiv : the preprint server for biology.

Upadhyay S, et al. (2025) Structure-based virtual screening identifies potent CD28 inhibitors that suppress T cell co-stimulation in cellular and mucosal models. European journal of medicinal chemistry, 300, 118194.

Calvo-Barreiro L, et al. (2025) Temperature-related intensity change (TRIC)-based high-throughput screening enables the discovery of small molecule CD28 binders. SLAS discovery : advancing life sciences R & D, 35, 100256.

Calvo-Barreiro L, et al. (2025) Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small Molecules. bioRxiv : the preprint server for biology.

Ketaren NE, et al. (2025) Unique mechanisms to increase structural stability and enhance antigen binding in nanobodies. *Structure* (London, England : 1993), 33(4), 677.

Fridy PC, et al. (2024) A new generation of nanobody research tools using improved mass spectrometry-based discovery methods. *The Journal of biological chemistry*, 300(9), 107623.

Ketaren NE, et al. (2024) Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus. *eLife*, 12.

Ketaren NE, et al. (2023) Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus. *bioRxiv : the preprint server for biology*.

Hosfelt J, et al. (2022) An allosteric inhibitor of bacterial Hsp70 chaperone potentiates antibiotics and mitigates resistance. *Cell chemical biology*, 29(5), 854.